We have heard from a number of Byetta users who are concerned that this drug played some role in their diagnosis of pancreatic cancer, pancreatitis, and thyroid cancer.
New York, New York (PRWEB) August 10, 2013
Bernstein Liebhard LLP is investigating Byetta lawsuits (http://www.byettalawsuit2013.com/) on behalf of patients who used the Type 2 diabetes medication and were later diagnosed with pancreatic cancer, pancreatitis or thyroid cancer. According to court documents, the manufacturers of Byetta are currently named in at least 40 federal lawsuits that allege the Defendants failed to provide doctors and patients with adequate warnings regarding a possible link between Byetta and pancreatic cancer, pancreatitis, and thyroid cancer. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is considering a proposal to establish a multidistrict litigation for all federally-filed product liability claims involving Byetta and similar Type 2 diabetes drugs. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)
“We have heard from a number of Byetta users who are concerned that this drug played some role in their diagnosis of pancreatic cancer, pancreatitis, and thyroid cancer. We expect the JPML to release a decision on the proposed multidistrict litigation very soon,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Byetta lawsuit reviews on behalf of any patient who may have been harmed by this medication.
Byetta and Pancreatic Cancer
Since its 2005 approval, the U.S. Food & Drug Administration (FDA) has released a number of Byetta warnings regarding its effects on the pancreas. In 2008, for example, the agency revealed that Byetta had been associated with a high number of adverse event reports involving pancreatitis.* Concerns about Byetta pancreatic cancer were heightened after March 14, 2013, when the FDA announced it was investigating findings from an unpublished study that suggested drugs like Byetta could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.
In April 2013, the Institute for Safe Medicine Practices (ISMP) reported that during a 12 month period that ended in June 2012, the FDA’s Adverse Event Reporting Database recorded 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta. The group also revealed that Byetta and similar Type 2 diabetes drugs known as incretin mimetics were 25 times more likely to be associated with reports of pancreatic cancer compared to other classes of diabetes medications.**
Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***
Patients treated with Byetta who developed pancreatitis, pancreatic cancer or thyroid cancer may be entitled to compensation for medical bills and other damages. Learn More about the possible link between Byetta and pancreatic cancer at Bernstein Liebhard LLP’s website. For a free Byetta lawsuit review, please call 800-511-5092.
*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008
**ismp.org/QuarterWatch/pdfs/2012Q3.pdf, ISMP, April 2013
***bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com